Triplet Combination for Breast Cancer Gets FDA Fast Track Designation

Ongoing clinical trials are evaluating zotatifin (eFT226) plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for the treatment of ER–positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted Fast Track Designation to eFFECTOR Therapeutics, Inc’s zotatifin (eFT226) plus Faslodex (fulvestrant)…